Tanaka Osamu, Kojima Takao, Ohbora Akihiro, Makita Chiyoko, Taniguchi Takuya, Ono Kousei, Matsuo Masayuki, Nagata Yasushi
Asahi University Hospital, Department of Radiation Oncology, Gifu, Japan.
Asahi University Hospital, Department of Gastroenterology, Gifu, Japan.
J Clin Exp Hepatol. 2020 Mar-Apr;10(2):101-105. doi: 10.1016/j.jceh.2019.05.002. Epub 2019 May 21.
Stereotactic body radiotherapy (SBRT) delivers high-dose radiation to tumor tissues in few fractions, thereby reducing radiation damage to at-risk organs. There are more potential effects of SBRT owing to the higher biological equivalent dose delivered. Herein, we retrospectively analyzed its effectiveness and toxicity at our institution.
Data from patients with hepatocellular carcinoma (HCC; n = 10) and liver metastases (n = 10) who underwent SBRT (total dose of 30-50 Gy in 5-10 fractions) between 2013 and 2016 were analyzed. Adverse events were recorded at the end of RT, 6 months after treatment, or upon death. Overall survival (OS) was calculated according to the biological effective dose (BED α/β = 10) and liver function (Child-Pugh [CP] classification 5 or 6 vs. 7 or 8) after SBRT, using Kaplan-Meier analyses.
Of the 20 patients, 6 declined the CP classification score after SBRT; grade 3 adverse events were not seen in any patient. A higher OS rate was seen in patients receiving a higher BED and in those with better CP classification after SBRT. Kaplan-Meier survival analysis yielded a median OS of 401 days and 1- and 2-year OS of 45% and 15%, respectively.
The higher BED was significantly associated with tumor control, and there were no differences in the tumor control rate between HCC and metastatic tumors. Changes in CP scores after SBRT also affected the survival rate. Good liver function may permit multiple rounds of SBRT.
立体定向体部放疗(SBRT)可在少数分次治疗中向肿瘤组织输送高剂量辐射,从而减少对危及器官的辐射损伤。由于所输送的生物等效剂量较高,SBRT存在更多潜在效应。在此,我们回顾性分析了其在本机构的有效性和毒性。
分析了2013年至2016年间接受SBRT(总剂量30 - 50 Gy,分5 - 10次)的肝细胞癌(HCC;n = 10)和肝转移瘤(n = 10)患者的数据。在放疗结束时、治疗后6个月或死亡时记录不良事件。使用Kaplan - Meier分析方法,根据SBRT后的生物有效剂量(BED α/β = 10)和肝功能(Child - Pugh [CP]分级5或6与7或8)计算总生存期(OS)。
20例患者中,6例在SBRT后拒绝进行CP分级评分;未观察到任何患者出现3级不良事件。接受较高BED的患者以及SBRT后CP分级较好的患者的OS率较高。Kaplan - Meier生存分析得出中位OS为401天,1年和2年OS分别为45%和15%。
较高的BED与肿瘤控制显著相关,HCC和转移性肿瘤之间的肿瘤控制率无差异。SBRT后CP评分的变化也影响生存率。良好的肝功能可能允许进行多轮SBRT。